 Secondary Efficacy Analysis: Similar analyses of covariance will be used to examine treatment group differences at week 16 compared with baseline for WOMAC subscales pain, stiffness and physical function, and Quality of Life assessments SF-36. Changes in the subjects well-being and overall global assessment will be compared using appropriate non-parametric tests, e.g. Mann-Whitney test or MacNemars test. Changes in attitudes and health beliefs to CAM will be assessed using Chi-Squared tests. 